Farmacy

Jan 8 2018

Forest Laboratories to Acquire Furiex Pharmaceuticals #king #pharma

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …

Jan 7 2018

DSM says plans to cut 1, 100 jobs prompted by recent pharma moves not shareholder

#dsm pharma # DSM says plans to cut 1,100 jobs prompted by recent pharma moves not shareholder pressure By Gareth MacDonald+ Gareth MACDONALD 25-Aug-2015 2015-08-25T00:00:00Z Last updated on 26-Aug-2015 at 13:46 GMT 2015-08-26T13:46:47Z Royal DSM will make up to 1100 staff redundant by the end of 2017 to cut costs following the formation of its Sinochem JV and pharma products deal with Patheon. The Dutch supplier announced the job cuts today, explaining that the move will save it €125m to €150m ($144m to $173m) over the next two years. DSM said around half of the job cuts will be at …

Jan 7 2018

UCB to buy Schwarz Pharma for $5 #biotech #company

#schwarz pharma # UCB to buy Schwarz Pharma for $5.6 billion LONDON (MarketWatch) — Belgium’s UCB on Monday said it agreed to pay $5.6 billion for Germany’s Schwarz Pharma, the third multibillion-dollar takeover in the European pharmaceutical industry in the past five days. UCB (000373953) said it’s paying 4.4 billion euros in cash and shares, representing a 20% premium to Friday’s close, for Schwarz Pharma (722190). The deal follows proposals by Germany’s Merck KGaA (659990) to buy Switzerland’s Serono SRA, +0.00% for $13.3 billion, and Denmark’s Nycomed to buy the pharmaceutical operations of Germany’s Altana AAA, +8.70% for $5.8 billion. …

Jan 7 2018

Actavis to Buy Forest Laboratories for $25 Billion #penn #pharma

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …

Jan 7 2018

Teva to buy Barr Pharma for more than $7b #hra #pharma

#barr pharma #from the September 2008 issue Teva to buy Barr Pharma for more than $7b. Teva Pharmaceutical confirmed its purchase of rival generic drugmaker Barr Pharmaceuticals for nearly $7.5 billion in a move that will boost Teva’s dominance as the world’s largest generic drugmaker. The deal continues consolidation of the generic-drug sector, driven by growth prospects as governments and other payers turn to the lower-priced medications and by the impending expiration of brand-name drug patents worth billions of dollars a year. Israel-based Teva Pharmaceutical Industries Ltd. said acquiring Montvale, N.J.-based Barr Pharmaceuticals Inc. the world’s No. 4 generic drug …

Jan 7 2018

Sun Pharma to buy Dusa for $230 million #schwarz #pharma

#dusa pharma # Sun Pharma to buy Dusa for $230 million Updated: Thu, Nov 08 2012. 11 43 PM IST Mumbai: Sun Pharmaceuticals Industries Ltd. India s most valuable drug maker, has agreed to buy US-based skincare speciality company DUSA Pharmaceuticals Inc. for $230 million ( Rs. 1,251 crore). Under the terms of the agreement, a subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a price of $8 per share in cash, a 38% premium to the closing price on 7 November, the Indian company said on Thursday. The transaction has …

Jan 7 2018

Horizon Pharma Raises CEO Walbert – s Pay 10-Fold to $93 #pharmaceutical #companies #in #san

#horizon pharma # Horizon Pharma Raises CEO Walbert’s Pay 10-Fold to $93.4 Million Horizon Pharma Plc gave Chief Executive Officer Timothy Walbert a $93.4 million pay package for 2015, a 10-fold increase from the previous year as the company came under scrutiny for its distribution practices. Walbert received stock options valued at $47.4 million and $43.5 million in restricted shares, according to a preliminary proxy filed Tuesday. The options and about a quarter of the shares will vest over four years, with the remaining stock vesting in 2018 if the firm meets performance targets. His pay package for 2014 was …

Jan 7 2018

How to get a chemical engineer job in the pharmaceutical industry #pharmaceutical #companies #in #dallas

#jobs pharmaceutical industry # ProClinical Life Sciences Recruitment Blog Interested in the pharmaceutical industry? We don’t blame you. According to the World Health Organization, “the global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within 3 years.” In other words, the pharmaceutical industry is booming, and the growth opportunities are truly endless. As a chemical engineer, you are an integral part to any pharmaceutical organisation. However, since the industry is so hot right now, getting your foot in the door can prove rather difficult. So, how do you get a job as …

Jan 7 2018

Amgen to Buy Onyx for $10 #pharma #headhunters

#onyx pharma # Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Amgen will pay $125 a share for Onyx’s outstanding stock, the companies said in a statement yesterday. Net of estimated Onyx cash, the deal is worth $9.7 billion. Onyx’s Kyprolis, approved last year for a rare blood cancer, may spur more than $3 billion in revenue by 2021, according to analyst estimates compiled by Bloomberg. …

Jan 6 2018

Sun Pharma sells two US-based plants, 15 products to Frontida BioPharm #pharmaceutical #industry

#sun pharma products # Sun Pharma sells two US-based plants, 15 products to Frontida BioPharm The move was made to consolidate Sun Pharma’s manufacturing operations in the US; the company hasn’t revealed financial details of the deal. Drug major Sun Pharmaceutical Industries has sold two of its US-based manufacturing facilities along with 15 products to Frontida BioPharm Inc for an undisclosed amount. As part of its manufacturing consolidation in the US, one of the company s wholly-owned subsidiaries entered into an agreement with Frontida BioPharm Inc for divestment of two oral solid dosage manufacturing facilities located at Philadelphia and Aurora, …